

# Application News

High Performance Liquid Chromatography

## High Speed Analysis of Nortriptyline in accordance with chapter 621 in USP 39

No. SCA 190 033

High throughput analysis has been advanced dramatically in recent years with the increasing necessity to improve productivity operational efficiency. Especially HPLC has also been in the spotlight thanks to significant in ultra-high-speed advances technology, in particular ultra-high performance LC and micro-particle column packing material. The recently revised General Chapter 621 of the United States Pharmacopoeia (USP 621) now permits a degree of adjustment of HPLC and GC parameters, specifically aimed to satisfy the requirements of system suitability. Taken account of USP 621, this Application News introduces an example of isocratic analysis of Nortriptyline monography in accordance with USP and still fulfilling the allowable adjustment criteria. Nortriptyline is a second-generation tricyclic antidepressant. It is used for medication of depression and childhood nocturnal enuresis. Additionally, an example of analysis that can be completed in a significantly shorter time than that described in the USP General Chapter 621 Chromatography is presented here.

### ■ Allowable adjustments to HPLC parameters

Table 1 shows the parameters which may be changed according to USP 621. The analysis was performed under isocratic conditions. Additionally, the actual permissible ranges within these LC parameters are shown.

#### ■ Speed enhancement for USP method

The permissible ranges within the analytical conditions may be modified and are specified in the USP General Chapters: <621> Chromatography. Changing these analytical conditions within the range makes it possible to

shorten the analysis time. For details regarding changes that can be used to allow fast USPcompliant analysis, please refer to Application News L464. Shortening analysis time can be accomplished in three ways, 1) by shortening the column, 2) by lowering the inner diameter and 3) by increasing the flowrate while maintaining the linear velocity. To preserve the resolution of the separation, the column length and particle size may be modified as long as the ratio of L (column length) to dp (column particle size) remains in the specified range (permissible range: -25 % to +50 %). For the original USP method, a column with the dimensions 250 mmL. x 4.6 mm I.D., and 5 µm particle size was used. We selected a column size of 150 mmL. x 3.0 mm I.D., and 3 µm particle size with constant L/dp ratio (Table 2). For further details, please see Table 3. The flowrate, proportional to the column cross-sectional area, and inversely proportional to the particle diameter (see text for permissible limits), was determined as 0.9 mL/min. Table 4 shows the analytical conditions.

Table 1: Allowable adjustments to HPLC parameters according to USP 621

Particle size(dp)	L/dp ratio constant or Theoretical	
Column length(L)	plate number: -25 to + 50%	
Column ID(dc)	Any allowed if linear velocity is constant	
Flowrate	Combination* of dp and dc : ±50%	
Injection Vol.	Can be adjusted as consistent with precision and detection limits	
Column Temp.	± 10 °C	

<sup>\*</sup>  $F_2 = F_1 \times [(dc_2^2 \times dp_1)/(dc_1^2 \times dp_2)]$ 

 $F_1$  and  $F_2$  are the flow rates for the original and modified conditions, respectively;  $dc_1$  and  $dc_2$  are the respective column diameters; and  $dp_1$  and  $dp_2$  are the particle sizes.

Table 2: Selection of column for speed enhancement

om and on one					
	Column size	L/dp	Ratio		
USP	250 x 4.6 mm	50000	1		
Original Method	5 µm		(100%)		
USP	150 x 3.0 mm	50000	1		
Fast Method	3 µm		(+0%)		

Table 3: Column selection for speed enhancement in case of fixing the particle size and column I.D.

	USP method of	Allowable range	Modified method	
Particle size(dp)	5 μm	3 µm	3 µm	
Column ID(dc)	4.6 mm	3 mm	3 mm	
Column length(L)	250 mm	112.5 - 225 mm	150 mm	
Flowrate	2.5 mL/min	0.89 – 2.66 mL/min	0.9 mL/min	
Injection Vol.	10 μL	Variable	5 μL	
Column Temp.	Unspecified	Variable	30 °C	

Table 4: Analytical conditions

System	LC-2040C 3D		
Column	(1) Shim-pack GIS CN (150 x 3.0 mm, 3 µm) (2) Shim-pack GIS CN (250 x 4.6 mm, 5 µm)		
Mobile phase	A) Acetonitrile B) Methanol C) Buffer A/B/C = 40/43/17 (v/v/v) **		
Flowrate	(1) 0.9 mL/min; (2) 2.5 mL/min		
Column Temp.	30 °C		
Injection Vol.	(1) 5 μL; (2) 10 μL		
Detection	LC-2030/2040 PDA; D2 at 190-350 nm		

#### ■ Results

The results are shown in Figure 1 and 2 and in Table 5. The speed enhancement is shown in Figure 1. Here, the retention time is much shorter with 5.3 minutes for Nortriptyline compared to the retention time in Figure 2 (6.2 minutes for Nortriptyline).

use of this publication.




Figure 1: Chromatogram of USP fast method for Nortriptyline (0.39 mg/mL) with column (1) Shimpack GIS CN (150 x 3.0 mm; 3 µm)




Figure 2: Chromatogram of USP original method for Nortriptyline (0.39 mg/mL) with column (2) Shim-pack GIS CN (250 x 4.6 mm; 5  $\mu$ m)

Table 5: Results of system suitability test using USP Method (original method and fast method).

OSF Method (original method and last method).						
System Suitability	Ref. Value	USP original Value		Fast method Value		
Theoretical plate number	≧500	4296	Pass	3874	Pass	
Tailing factor	≦3	1.33	Pass	1.83	Pass	
RSD	≦2.0%	0.03	Pass	0.09	Pass	

#### ■ Conclusion

With the fast USP method, the original USP method, according to the reference value, was improved because the analysis time is shorter and solvent consumption is reduced. Ongoing with this, the cost per analysis is reduced significantly. Additionally, both column conditions are better than the USP reference.



This publication may contain references to products that are not available in your county. Please contact us to check the availability of these products in your country.

Company names, products/service names and logos used in this publication are trademarks and trade names of Shimadzu Company is subsidiaries or its affiliates, whether or not they are used with trademark symbol "TM" or "6".

For Research Use Only. Not for use in diagnostic procedures. Not available in the USA, Canada, and China

Company names, products/service names and logos used in this publication are trademarks and trade names of Shimadzu Corporation, its subsidiaries or its affiliates, whether or not they are used with trademark symbol "TM" or "®". Third-party trademarks and trade names may be used in this publication to refer to either the entities or their products/services, whether or not they are used with trademark symbol "TM" or "®". Shimadzu disclaims any proprietary interest in trademarks and trade names other than its own.

The content of this publication are provided to you "as is" without warranty of any kind, and are subject to change without notice. Shimadzu does not assume any responsibility or liability for any damage, whether direct or indirect, relating to the